Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3689 - 3696 of 12093 results
In Case You Missed It: The Influence of Bioethics in Research and Development
October 27, 2020| Blog| Viewpoint
Avoiding IPR Institution: Your Best Defense to an IPR Challenge
October 27, 2020| Blog| Viewpoint
Procuring U.S. Patents without a Signed Assignment of Patent Rights
October 27, 2020| Blog| Viewpoint
You Can’t Always Get What You Want: The End of ESG Investing in ERISA Accounts
October 26, 2020| Blog| Viewpoint
The Art of An SEP War: A Chinese IP Court’s Recent Use of Anti-Suit Injunction Invites A Battle that It Likely Won’t Win
October 26, 2020| Blog| Viewpoint
New York State Addresses Paid Sick Leave Requirements in New Guidance
October 23, 2020| Blog| Viewpoint
The Department of State Proposes to Eliminate B-1 in Lieu of H Visa Classifications
October 23, 2020| Blog| Viewpoint
REMINDER: Massachusetts Paid Family and Medical Leave Next Steps
October 23, 2020| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|